Opinion of the Transparency Council – candesartan + hydrochlorothiazide

At its meeting on 8 May 2023, the Transparency Council adopted Opinion No. 78/2023 on the inclusion in the reimbursement procedure of medicines containing the active substances candesartan + hydrochlorothiazide for selected off-label indications. 

Publication on the list of opinions on active substances for off-label indications